Psychostimulants for Depression in Serious Illness: Limited Evidence, Select Indications

Area of Science:

• Palliative Care
• Psychiatry
• Oncology

Background:

• Depression is prevalent in serious illness, but conventional antidepressants have a slow onset of action.
• Psychostimulants may offer faster symptom relief for major depressive disorder (MDD).

Purpose of the Study:

• To review the evidence for psychostimulant use in MDD, including in patients with cancer or serious illnesses.
• To evaluate psychostimulants as monotherapy versus augmentation for depression.

Main Methods:

• Systematic review and meta-analysis of clinical trials.
• Inclusion of studies on patients with cancer and other serious illnesses.
• Assessment of psychostimulants for MDD, both alone and combined with other treatments.

Main Results:

• Monotherapy evidence is weak, with meta-analyses showing modest benefits over placebo in limited trials.
• Augmentation studies show statistically significant but clinically small effects.
• Data in serious illness populations are scarce and findings are inconsistent.

Conclusions:

• Psychostimulants have limited evidence for treating depression in serious illness, especially as monotherapy.
• Alternative rapid-acting interventions like ketamine/esketamine or antipsychotic augmentation may be more suitable.
• Psychostimulants should be used cautiously, reserved for specific cases like comorbid ADHD or previous positive responses.